Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
551 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hypertension - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertension - Pipeline Review, H2 2016, provides an overview of the Hypertension (Cardiovascular) pipeline landscape. Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 32, 28, 26, 85 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 8 molecules, respectively. Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular). - The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 7 Hypertension Overview 8 Therapeutics Development 9 Hypertension - Therapeutics under Development by Companies 11 Hypertension - Therapeutics under Investigation by Universities/Institutes 19 Hypertension - Pipeline Products Glance 21 Hypertension - Products under Development by Companies 24 Hypertension - Products under Investigation by Universities/Institutes 37 Hypertension - Companies Involved in Therapeutics Development 39 Hypertension - Therapeutics Assessment 146 Drug Profiles 168 Hypertension - Dormant Projects 486 Hypertension - Discontinued Products 512 Hypertension - Product Development Milestones 515 Appendix 527
List of Tables
Number of Products under Development for Hypertension, H2 2016 32 Number of Products under Development for Hypertension - Comparative Analysis, H2 2016 33 Number of Products under Development by Companies, H2 2016 34 Number of Products under Development by Companies, H2 2016 (Contd..1) 35 Number of Products under Development by Companies, H2 2016 (Contd..2) 36 Number of Products under Development by Companies, H2 2016 (Contd..3) 37 Number of Products under Development by Companies, H2 2016 (Contd..4) 38 Number of Products under Development by Companies, H2 2016 (Contd..5) 39 Number of Products under Development by Companies, H2 2016 (Contd..6) 40 Number of Products under Development by Companies, H2 2016 (Contd..7) 41 Number of Products under Investigation by Universities/Institutes, H2 2016 43 Comparative Analysis by Late Stage Development, H2 2016 44 Comparative Analysis by Clinical Stage Development, H2 2016 45 Comparative Analysis by Early Stage Development, H2 2016 46 Products under Development by Companies, H2 2016 47 Products under Development by Companies, H2 2016 (Contd..1) 48 Products under Development by Companies, H2 2016 (Contd..2) 49 Products under Development by Companies, H2 2016 (Contd..3) 50 Products under Development by Companies, H2 2016 (Contd..4) 51 Products under Development by Companies, H2 2016 (Contd..5) 52 Products under Development by Companies, H2 2016 (Contd..6) 53 Products under Development by Companies, H2 2016 (Contd..7) 54 Products under Development by Companies, H2 2016 (Contd..8) 55 Products under Development by Companies, H2 2016 (Contd..9) 56 Products under Development by Companies, H2 2016 (Contd..10) 57 Products under Development by Companies, H2 2016 (Contd..11) 58 Products under Development by Companies, H2 2016 (Contd..12) 59 Products under Investigation by Universities/Institutes, H2 2016 60 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 61 Hypertension - Pipeline by A1M Pharma AB, H2 2016 62 Hypertension - Pipeline by AbbVie Inc, H2 2016 63 Hypertension - Pipeline by Actelion Ltd, H2 2016 64 Hypertension - Pipeline by Afferent Pharmaceuticals Inc, H2 2016 65 Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 66 Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H2 2016 67 Hypertension - Pipeline by AnGes MG Inc, H2 2016 68 Hypertension - Pipeline by APT Therapeutics Inc, H2 2016 69 Hypertension - Pipeline by Arena Pharmaceuticals Inc, H2 2016 70 Hypertension - Pipeline by Ascendis Pharma A/S, H2 2016 71 Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H2 2016 72 Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 73 Hypertension - Pipeline by Bayer AG, H2 2016 74 Hypertension - Pipeline by Bial - Portela & Ca SA, H2 2016 75 Hypertension - Pipeline by Biolab Farmaceutica Ltda, H2 2016 76 Hypertension - Pipeline by BioRestorative Therapies Inc, H2 2016 77 Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016 78 Hypertension - Pipeline by Cellceutix Corp, H2 2016 79 Hypertension - Pipeline by Celsion Corp, H2 2016 80 Hypertension - Pipeline by Celtaxsys Inc, H2 2016 81 Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 82 Hypertension - Pipeline by CJ HealthCare Corp, H2 2016 83 Hypertension - Pipeline by Complexa Inc, H2 2016 84 Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H2 2016 85 Hypertension - Pipeline by Corion Biotech Srl, H2 2016 86 Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H2 2016 87 Hypertension - Pipeline by Cytokinetics Inc, H2 2016 88 Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 89 Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 90 Hypertension - Pipeline by DiaMedica Inc, H2 2016 91 Hypertension - Pipeline by Eli Lilly and Company, H2 2016 92 Hypertension - Pipeline by Esperion Therapeutics Inc, H2 2016 93 Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 94 Hypertension - Pipeline by Ferring International Center SA, H2 2016 95 Hypertension - Pipeline by Galectin Therapeutics Inc, H2 2016 96 Hypertension - Pipeline by Genextra Spa, H2 2016 97 Hypertension - Pipeline by Gilead Sciences Inc, H2 2016 98 Hypertension - Pipeline by GlaxoSmithKline Plc, H2 2016 99 Hypertension - Pipeline by Glenveigh Medical LLC, H2 2016 100 Hypertension - Pipeline by HanAll Biopharma Co Ltd, H2 2016 101 Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 102 Hypertension - Pipeline by HitGen LTD, H2 2016 103 Hypertension - Pipeline by Innopharmax Inc, H2 2016 104 Hypertension - Pipeline by Insmed Inc, H2 2016 105 Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H2 2016 106 Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 107 Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H2 2016 108 Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016 109 Hypertension - Pipeline by Johnson & Johnson, H2 2016 110 Hypertension - Pipeline by JW Pharmaceutical Corp, H2 2016 111 Hypertension - Pipeline by Kowa Company Ltd, H2 2016 112 Hypertension - Pipeline by Leading BioSciences Inc, H2 2016 113 Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2016 114 Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2016 115 Hypertension - Pipeline by LFB SA, H2 2016 116 Hypertension - Pipeline by LG Life Science LTD, H2 2016 117 Hypertension - Pipeline by LinXis BV, H2 2016 118 Hypertension - Pipeline by Liquidia Technologies Inc, H2 2016 119 Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016 120 Hypertension - Pipeline by MannKind Corp, H2 2016 121 Hypertension - Pipeline by Mast Therapeutics Inc, H2 2016 122 Hypertension - Pipeline by Merck & Co Inc, H2 2016 123 Hypertension - Pipeline by Mezzion Pharma Co Ltd, H2 2016 124 Hypertension - Pipeline by miRagen Therapeutics Inc, H2 2016 125 Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016 126 Hypertension - Pipeline by Morphogen-IX Ltd, H2 2016 127 Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 128 Hypertension - Pipeline by Nippon Kayaku Co Ltd, H2 2016 129 Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H2 2016 130 Hypertension - Pipeline by Novartis AG, H2 2016 131 Hypertension - Pipeline by Noxamet Ltd, H2 2016 132 Hypertension - Pipeline by Omeros Corp, H2 2016 133 Hypertension - Pipeline by Peloton Therapeutics Inc, H2 2016 134 Hypertension - Pipeline by Pfizer Inc, H2 2016 135 Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H2 2016 136 Hypertension - Pipeline by Pluristem Therapeutics Inc, H2 2016 137 Hypertension - Pipeline by Polyphor Ltd, H2 2016 138 Hypertension - Pipeline by Proteo Inc, H2 2016 139 Hypertension - Pipeline by Pulmokine Inc, H2 2016 140 Hypertension - Pipeline by Quantum Genomics SA, H2 2016 141 Hypertension - Pipeline by Reata Pharmaceuticals Inc, H2 2016 142 Hypertension - Pipeline by RedHill Biopharma Ltd, H2 2016 143 Hypertension - Pipeline by Respira Therapeutics Inc, H2 2016 144 Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H2 2016 145 Hypertension - Pipeline by Sanofi, H2 2016 146 Hypertension - Pipeline by Selten Pharma Inc, H2 2016 147 Hypertension - Pipeline by Serodus ASA, H2 2016 148 Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 149 Hypertension - Pipeline by Silence Therapeutics Plc, H2 2016 150 Hypertension - Pipeline by Simcere Pharmaceutical Group, H2 2016 151 Hypertension - Pipeline by SteadyMed Therapeutics Inc, H2 2016 152 Hypertension - Pipeline by Suda Ltd, H2 2016 153 Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 154 Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 155 Hypertension - Pipeline by The Medicines Company, H2 2016 156 Hypertension - Pipeline by Theravance Biopharma Inc, H2 2016 157 Hypertension - Pipeline by Toray Industries Inc, H2 2016 158 Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H2 2016 159 Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H2 2016 160 Hypertension - Pipeline by United Therapeutics Corp, H2 2016 161 Hypertension - Pipeline by VBS Pharmaceuticals, H2 2016 162 Hypertension - Pipeline by Vectura Group Plc, H2 2016 163 Hypertension - Pipeline by VG Life Sciences Inc, H2 2016 164 Hypertension - Pipeline by Vicore Pharma AB, H2 2016 165 Hypertension - Pipeline by XORTX Pharma Corp, H2 2016 166 Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H2 2016 167 Hypertension - Pipeline by Yuhan Corp, H2 2016 168 Assessment by Monotherapy Products, H2 2016 169 Assessment by Combination Products, H2 2016 170 Number of Products by Stage and Target, H2 2016 172 Number of Products by Stage and Mechanism of Action, H2 2016 180 Number of Products by Stage and Route of Administration, H2 2016 188 Number of Products by Stage and Molecule Type, H2 2016 190 Hypertension - Dormant Projects, H2 2016 509 Hypertension - Dormant Projects (Contd..1), H2 2016 510 Hypertension - Dormant Projects (Contd..2), H2 2016 511 Hypertension - Dormant Projects (Contd..3), H2 2016 512 Hypertension - Dormant Projects (Contd..4), H2 2016 513 Hypertension - Dormant Projects (Contd..5), H2 2016 514 Hypertension - Dormant Projects (Contd..6), H2 2016 515 Hypertension - Dormant Projects (Contd..7), H2 2016 516 Hypertension - Dormant Projects (Contd..8), H2 2016 517 Hypertension - Dormant Projects (Contd..9), H2 2016 518 Hypertension - Dormant Projects (Contd..10), H2 2016 519 Hypertension - Dormant Projects (Contd..11), H2 2016 520 Hypertension - Dormant Projects (Contd..12), H2 2016 521 Hypertension - Dormant Projects (Contd..13), H2 2016 522 Hypertension - Dormant Projects (Contd..14), H2 2016 523 Hypertension - Dormant Projects (Contd..15), H2 2016 524 Hypertension - Dormant Projects (Contd..16), H2 2016 525 Hypertension - Dormant Projects (Contd..17), H2 2016 526 Hypertension - Dormant Projects (Contd..18), H2 2016 527 Hypertension - Dormant Projects (Contd..19), H2 2016 528 Hypertension - Dormant Projects (Contd..20), H2 2016 529 Hypertension - Dormant Projects (Contd..21), H2 2016 530 Hypertension - Dormant Projects (Contd..22), H2 2016 531 Hypertension - Dormant Projects (Contd..23), H2 2016 532 Hypertension - Dormant Projects (Contd..24), H2 2016 533 Hypertension - Dormant Projects (Contd..25), H2 2016 534 Hypertension - Discontinued Products, H2 2016 535 Hypertension - Discontinued Products (Contd..1), H2 2016 536 Hypertension - Discontinued Products (Contd..2), H2 2016 537
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
